Evidence map›Paper›PMID 24015915›Full record

Trial reportInternational journal of stroke : official journal of the International Stroke Society2014

Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS).

Yoji Nagai, Tatsuo Kohriyama, Hideki Origasa, Kazuo Minematsu, Chiaki Yokota, Shinichiro Uchiyama, Setsuro Ibayashi, Yasuo Terayama, Makoto Takagi, Kazuo Kitagawa and 14 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of stroke : official journal of the International Stroke Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yoji NagaiFoundation for Biomedical Research and Innovation Translational Research Informatics Center, Kobe, Japan.
Tatsuo Kohriyama
Hideki Origasa
Kazuo Minematsu
Chiaki Yokota
Shinichiro Uchiyama
Setsuro Ibayashi
Yasuo Terayama
Makoto Takagi
Kazuo Kitagawa
Eiichi Nomura
Naohisa Hosomi
Toshiho Ohtsuki
Takemori Yamawaki
Yoshihiro Matsubara
Masakazu Nakamura
Yoshimitsu Yamasaki
Etsuro Mori
Masanori Fukushima
Shotai Kobayashi
Yukito Shinohara
Takenori Yamaguchi
Masayasu Matsumoto
J-STARS Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough statin therapy is beneficial for preventing first strokes, the benefit for recurrent stroke and its sub-types remains unknown in Asian populations. The aim of this study is to examine the role of pravastatin in the secondary prevention of stroke in Japanese patients.

methodsThis is a multicenter, randomized, open-label, parallel group study of patients with noncardioembolic ischemic stroke (atherothrombotic infarction, lacunar infarction, and infarction of undetermined etiology). All patients were diagnosed with hyperlipidemia and with a total cholesterol level between 180 and 240 mg/dl at enrollment. Patients in the treatment group receive 10 mg/day of pravastatin, and those in the control group receive no statin treatment. The primary end-point is the recurrence of stroke, including transient ischemic attack. The secondary end-points include the onset of respective stroke sub-types and functional outcomes related to stroke. The patients were enrolled for five-years and will be followed up for five-years.

resultsA total of 1578 eligible patients (age: 66·2 years, men: 68·8%), including 64·2% with lacunar infarction, 25·4% with atherothrombotic infarction, and 10·4% with infarction of undetermined etiology were included in this study. Lipid levels were generally well controlled (total cholesterol: 210·0 mg/dl, low density lipoprotein cholesterol: 129·5 mg/dl) at baseline. In addition, the disability of patients was relatively mild, and cognitive function was preserved in the majority of patients.

conclusionThis article reports the rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke. Follow-ups of patients are in progress and will end in 2014.

Indexed as

AdultAgedAged, 80 and overAnticholesteremic AgentsEnzyme InhibitorsFemaleHumansJapanLongitudinal StudiesMaleMiddle AgedOutpatientsPravastatinSecondary PreventionSeverity of Illness IndexStatistics, NonparametricAnticholesteremic AgentsEnzyme InhibitorsPravastatinrecurrencesecondary preventionstatinsstroke

Identifiers

PMID24015915
PMCPMC4283729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.